S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.21
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.51
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
COLL · Collegium Pharmaceutical, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Collegium Pharmaceutical Inc (COLL)
NASDAQ NMS - GLOBAL MARKET
Pharmaceuticals
$22.90
-0.35
(-1.51%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$22.90
$22.57
$23.04
52-WEEK RANGE
$22.90
$21.43
$50.79
What's happening
- COLL is down 1.51% today, trading at $22.90. — Live quote
- Volume today (25,816) is well below its 3-month average of 691,100. (Finnhub fundamentals)
- Reports earnings on 2026-11-05, 14 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $1.92 actual vs. $1.75 estimated (+9.7%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 5
Buy 7
Hold 2
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (14 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
COLL
-49.83%
vs S&P 500
-62.60%
1-YEAR RETURN
COLL
-33.34%
vs S&P 500
-47.90%
6-MONTH RETURN
COLL
-29.69%
3-MONTH RETURN
COLL
-35.20%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$1.92
Est. $1.75
BEAT +9.7%
2026-04-26 (Q1 2026)
$1.76
Est. $1.62
BEAT +8.4%
2026-01-26 (Q4 2025)
$2.04
Est. $2.37
MISS -14.1%
2025-10-26 (Q3 2025)
$2.25
Est. $2.08
BEAT +7.9%
Valuation Measures & Ratios
Enterprise Value4$1.83B
Forward P/E53.34
PEG Ratio63.79
Price / Sales (TTM1)0.92
Price / Book73.76
EV4 / Revenue2.27
EV4 / EBITDA12.57
Profit Margin5.93%
Operating Margin17.50%
Return on Equity (ROE8)15.96%
Return on Assets (ROA9)2.72%
Avg Volume (3M)691,100
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 |
|---|---|---|---|---|---|
| Market cap | $1.19B | $1.20B | $1.71B | $1.31B | $1.04B |
| P/E | 24.74 | 15.97 | 27.15 | 22.43 | 28.74 |
| Price/Sales | 1.47 | 1.50 | 2.19 | 1.73 | 1.47 |
| Price/Book | 3.80 | 3.83 | 5.66 | 4.77 | 4.49 |
| EV/Revenue | 1.31 | 1.17 | 1.89 | 1.53 | 1.31 |
| ROE | 15.36% | 23.99% | 20.84% | 21.27% | 15.62% |
| ROA | 2.24% | 4.54% | 3.79% | 3.64% | 2.28% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short5,516,880
Change from Prior Settlement-2.79%
% of Float—
Days to Cover (Short Ratio)6.06
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 6.3% on the provider's reported measure. Finnhub fundamentals ↗
- Latest SEC filing is Form 8-K, filed 2026-10-19; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is 5.9%. Finnhub fundamentals ↗
- Trailing 52-week price return is -33.3%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on COLL
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $199.9M | $193.5M | $205.4M | $209.4M | $188.0M | $177.8M | $181.9M | $159.3M |
| Gross profit | $110.3M | $117.2M | $128.4M | $129.2M | $108.4M | $97.3M | $98.3M | $96.8M |
| Operating income | $3.7M | $30.9M | $60.8M | $62.1M | $35.1M | $21.7M | $38.1M | $34.8M |
| Net income | -$15.1M | $14.5M | $17.0M | $31.5M | $12.0M | $2.4M | $12.5M | $9.3M |
| EPS (diluted) | $-0.46 | $0.40 | $0.46 | $0.84 | $0.34 | $0.07 | $0.36 | $0.27 |
| EPS (basic) | $-0.46 | $0.45 | $0.54 | $1.00 | $0.38 | $0.08 | $0.39 | $0.29 |
| Operating margin | $2 | $16 | $30 | $30 | $19 | $12 | $21 | $22 |
| Net margin | -$8 | $7 | $8 | $15 | $6 | $1 | $7 | $6 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $2.14B | $1.65B | $1.66B | $1.61B | $1.59B | $1.63B | $1.66B | $1.64B |
| Total liabilities | $1.82B | $1.34B | $1.36B | $1.33B | $1.36B | $1.40B | $1.43B | $1.40B |
| Stockholders' equity | $311.9M | $312.4M | $301.7M | $274.8M | $232.2M | $234.4M | $228.8M | $234.3M |
| Total current assets | $608.0M | $745.7M | $691.4M | $613.9M | $549.2M | $527.6M | $482.3M | $443.8M |
| Total current liabilities | $589.9M | $435.0M | $440.0M | $452.9M | $464.6M | $486.7M | $509.5M | $459.4M |
| Cash & equivalents | $129.5M | $268.6M | $231.3M | $150.1M | $117.3M | $96.2M | $70.6M | $39.0M |
| Marketable securities (current) | $0 | $153.1M | $155.4M | $135.8M | $104.8M | $101.6M | $92.2M | $81.0M |
| Accounts receivable | $285.1M | $228.8M | $211.3M | $233.9M | $213.0M | $228.7M | $228.5M | $228.5M |
| Inventory | $113.3M | $42.7M | $40.9M | $38.1M | $38.1M | $37.2M | $35.6M | $38.0M |
| Other current assets | — | — | $3.2M | — | — | — | $2.7M | — |
| Property, plant & equipment | $10.7M | $11.7M | $12.0M | $12.2M | $12.9M | $13.8M | $14.3M | $14.6M |
| Goodwill | $190.2M | $145.9M | $145.9M | $145.9M | $147.9M | $150.8M | $162.3M | $146.0M |
| Intangible assets | $1.19B | $614.0M | $669.5M | $725.0M | $780.5M | $835.9M | $891.4M | $946.9M |
| Other non-current assets | $15.2M | $16.1M | $20.2M | $2.3M | $3.8M | $5.0M | $8.4M | $4.2M |
| Accounts payable | $9.2M | $6.8M | $10.7M | $7.6M | $10.9M | $17.9M | $3.9M | $3.1M |
| Accrued liabilities | $71.2M | $58.1M | $62.5M | $51.5M | $59.4M | $53.7M | $72.1M | $47.6M |
| Deferred revenue (current) | $667.0K | $667.0K | $667.0K | $667.0K | — | — | $0 | — |
| Long-term debt | — | — | — | — | — | — | — | — |
| Other non-current liabilities | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $41.0K | $41.0K | $41.0K | $41.0K | $40.0K | $40.0K | $40.0K | $40.0K |
| Retained earnings | -$101.7M | -$86.6M | -$101.1M | -$118.1M | -$149.6M | -$161.6M | -$164.0M | -$176.5M |
| Accumulated other comprehensive income (loss) | $0 | -$219.0K | $319.0K | $292.0K | $337.0K | $241.0K | $55.0K | $393.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $71.3M | $57.1M | $123.0M | $78.4M | $72.4M | $55.4M | $84.6M | -$9.0M |
| Investing cash flow | -$502.6M | $1.6M | -$20.1M | -$30.9M | -$2.9M | -$9.7M | -$11.8M | -$249.0M |
| Financing cash flow | $292.1M | -$21.3M | -$21.8M | -$14.8M | -$48.4M | -$25.2M | -$41.3M | $149.0M |
| Free cash flow | $70.8M | $56.8M | $122.4M | $78.2M | $72.4M | $54.6M | $84.1M | -$9.2M |
| Capital expenditures | $496.0K | $270.0K | $689.0K | $188.0K | $65.0K | $798.0K | $570.0K | $244.0K |
| Depreciation & amortization | — | — | — | — | — | — | — | — |
| Share-based compensation | $14.5M | $10.9M | $9.8M | $9.8M | $10.8M | $11.5M | $7.6M | $7.3M |
| Deferred income taxes | -$7.2M | -$968.0K | -$10.1M | -$12.1M | -$2.9M | -$539.0K | -$10.2M | -$8.7M |
| Change in accounts receivable | -$2.1M | $17.4M | -$22.6M | $20.9M | -$15.7M | $170.0K | -$106.0K | $190.0K |
| Change in inventory | $597.0K | $1.8M | $2.9M | -$96.0K | $930.0K | $1.7M | -$2.5M | -$7.0M |
| Change in accounts payable | $317.0K | -$3.8M | $3.0M | -$3.3M | -$7.0M | $13.9M | $810.0K | -$5.9M |
| Purchases of investments | $2.0M | $18.1M | $39.2M | $45.2M | $16.6M | $25.9M | $27.2M | $10.6M |
| Sales/maturities of investments | $151.8M | — | — | $0 | $0 | $0 | — | — |
| Share repurchases | $0 | — | $0 | $25.1M | $25.1M | — | $25.0M | $0 |
| Debt issued | — | — | — | — | — | — | — | — |
| Debt repaid | — | — | — | — | — | — | — | — |
| Tax withholding on stock comp | $646.0K | $15.4M | $861.0K | $964.0K | $428.0K | $10.6M | $279.0K | $142.0K |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $780.6M | $631.4M | $566.8M | $463.9M | $276.9M |
| Gross profit | $463.3M | $377.3M | $326.2M | $209.5M | $150.6M |
| Operating income | $179.6M | $169.9M | $167.0M | $33.3M | $17.6M |
| Net income | $62.9M | $69.2M | $48.2M | -$25.0M | $71.5M |
| EPS (diluted) | $1.73 | $1.86 | $1.29 | $-0.74 | $1.86 |
| EPS (basic) | $1.98 | $2.14 | $1.43 | $-0.74 | $2.05 |
| Operating margin | $23 | $27 | $29 | $7 | $6 |
| Net margin | $8 | $11 | $8 | -$5 | $26 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $1.66B | $1.66B | $1.14B | $1.17B | $692.1M |
| Total liabilities | $1.36B | $1.43B | $947.9M | $979.3M | $489.1M |
| Stockholders' equity | $301.7M | $228.8M | $195.4M | $194.8M | $202.9M |
| Total current assets | $691.4M | $482.3M | $537.6M | $420.0M | $315.5M |
| Total current liabilities | $440.0M | $509.5M | $457.9M | $433.7M | $279.6M |
| Cash & equivalents | $231.3M | $70.6M | $238.9M | $173.7M | $186.4M |
| Marketable securities (current) | $155.4M | $92.2M | $71.6M | — | — |
| Accounts receivable | $211.3M | $228.5M | $179.5M | $183.1M | $105.8M |
| Inventory | $40.9M | $35.6M | $32.3M | $46.5M | $17.4M |
| Other current assets | $3.2M | $2.7M | $93.0K | $57.0K | $27.0K |
| Property, plant & equipment | $12.0M | $14.3M | $16.0M | $19.5M | $19.5M |
| Goodwill | $145.9M | $162.3M | $133.9M | $133.7M | — |
| Intangible assets | $669.5M | $891.4M | $421.7M | $567.5M | $268.7M |
| Other non-current assets | $20.2M | $8.4M | $825.0K | $100.0K | $87.0K |
| Accounts payable | $10.7M | $3.9M | $8.7M | $3.5M | $4.2M |
| Accrued liabilities | $62.5M | $72.1M | $37.6M | $36.1M | $29.2M |
| Deferred revenue (current) | $667.0K | $0 | — | — | — |
| Long-term debt | — | — | — | — | — |
| Other non-current liabilities | — | — | — | — | — |
| Common stock & paid-in capital | $41.0K | $40.0K | $38.0K | $37.0K | $36.0K |
| Retained earnings | -$101.1M | -$164.0M | -$233.2M | -$281.3M | -$256.3M |
| Accumulated other comprehensive income (loss) | $319.0K | $55.0K | $14.0K | — | — |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | $329.3M | $205.0M | $274.7M | $124.2M | $103.6M |
| Investing cash flow | -$63.5M | -$287.8M | -$70.8M | -$573.7M | -$1.9M |
| Financing cash flow | -$110.2M | -$60.6M | -$140.2M | $436.7M | -$89.3M |
| Free cash flow | $327.6M | $203.3M | $274.3M | $122.6M | $101.6M |
| Capital expenditures | $1.7M | $1.7M | $461.0K | $1.6M | $1.9M |
| Depreciation & amortization | — | — | — | — | — |
| Share-based compensation | $41.9M | $32.4M | $27.1M | $22.9M | $24.3M |
| Deferred income taxes | -$25.7M | -$26.8M | -$2.2M | -$8.4M | -$78.0M |
| Change in accounts receivable | -$17.2M | $4.4M | -$3.6M | $21.8M | $22.5M |
| Change in inventory | $5.4M | -$13.9M | -$14.2M | -$48.3M | $2.3M |
| Change in accounts payable | $6.7M | -$11.3M | $5.1M | -$707.0K | -$5.8M |
| Purchases of investments | $127.0M | $111.2M | $92.4M | — | — |
| Sales/maturities of investments | — | — | $0 | — | — |
| Share repurchases | $25.1M | $60.0M | $75.0M | $14.1M | $47.9M |
| Debt issued | — | — | — | — | — |
| Debt repaid | — | — | — | — | — |
| Tax withholding on stock comp | $12.8M | $19.2M | $8.4M | $4.0M | $4.1M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding COLL as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-11-06 to 2026-06-08
Recent transactions
- Insiders have net sold 17,347 shares over the last 182 days, across 0 purchases and 4 sales.
- Most recent: SANTINI GINO (Reporting person) — Option exercise of 8,700 shares on 2026-06-08.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)17,347 sh(4 txns)
Net Shares-17,347
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| SANTINI GINO | Reporting person | Option exercise | 2026-06-08 | 8,700 |
| Freund John Gordon | Reporting person | Open market sale | 2026-05-18 | 20 |
| Lurker Nancy | Reporting person | Grant / award | 2026-05-14 | 8,741 |
| Paya Carlos V | Reporting person | Grant / award | 2026-05-14 | 8,741 |
| Glancy Donovan Michael | Reporting person | Grant / award | 2026-05-14 | 17,482 |
| BOHLIN GAREN G | Reporting person | Grant / award | 2026-05-14 | 8,741 |
| Balice-Gordon Rita J. | Reporting person | Grant / award | 2026-05-14 | 8,741 |
| Dieter David | EVP & General Counsel | Open market sale | 2026-03-18 | 13,976 |
| Dreyer Scott | EVP & Chief Commercial Officer | Open market sale | 2026-03-03 | 46,417 |
| Karnani Vikram | President and CEO | Grant / award | 2026-02-10 | 79,264 |
| Smith Thomas B | EVP and Chief Medical Officer | Grant / award | 2026-02-10 | 14,268 |
| Tupper Colleen | EVP & Chief Financial Officer | Grant / award | 2026-02-10 | 26,421 |
| Fallon John A. | Reporting person | Option exercise | 2025-11-12 | 15,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-06-08 | SANTINI GINO | Reporting person | Option exercise | 8,700 | $16.49 |
| 2026-05-18 | Freund John Gordon | Reporting person | Open market sale | 20 | $34.05 |
| 2026-05-15 | Freund John Gordon | Reporting person | Option exercise | 8,700 | $16.49 |
| 2026-05-15 | Freund John Gordon | Reporting person | Open market sale | 4,127 | $34.54 |
| 2026-05-14 | Lurker Nancy | Reporting person | Grant / award | 8,741 | $0.00 |
| 2026-05-14 | Paya Carlos V | Reporting person | Grant / award | 8,741 | $0.00 |
| 2026-05-14 | Freund John Gordon | Reporting person | Grant / award | 8,741 | $0.00 |
| 2026-05-14 | Glancy Donovan Michael | Reporting person | Grant / award | 17,482 | $0.00 |
| 2026-05-14 | BOHLIN GAREN G | Reporting person | Grant / award | 8,741 | $0.00 |
| 2026-05-14 | Balice-Gordon Rita J. | Reporting person | Grant / award | 8,741 | $0.00 |
| 2026-05-14 | SANTINI GINO | Reporting person | Grant / award | 8,741 | $0.00 |
| 2026-05-13 | Lurker Nancy | Reporting person | Open market sale | 4,500 | $35.97 |
| 2026-05-11 | BOHLIN GAREN G | Reporting person | Option exercise | 8,700 | $16.49 |
| 2026-05-11 | BOHLIN GAREN G | Reporting person | Open market sale | 8,700 | $37.18 |
| 2026-03-18 | Dieter David | EVP & General Counsel | Open market sale | 13,976 | $34.92 |
| 2026-03-17 | Dieter David | EVP & General Counsel | Tax withholding | 8,840 | $35.72 |
| 2026-03-09 | Dieter David | EVP & General Counsel | Open market sale | 6,224 | $36.65 |
| 2026-03-03 | Dreyer Scott | EVP & Chief Commercial Officer | Open market sale | 46,417 | $40.36 |
| 2026-03-03 | Dreyer Scott | EVP & Chief Commercial Officer | Open market sale | 3,559 | $40.99 |
| 2026-02-10 | Dieter David | EVP & General Counsel | Grant / award | 22,194 | $0.00 |
| 2026-02-10 | Dieter David | EVP & General Counsel | Grant / award | 9,005 | $0.00 |
| 2026-02-10 | Dieter David | EVP & General Counsel | Tax withholding | 2,781 | $46.75 |
| 2026-02-10 | Karnani Vikram | President and CEO | Grant / award | 79,264 | $0.00 |
| 2026-02-10 | Karnani Vikram | President and CEO | Grant / award | 32,531 | $0.00 |
| 2026-02-10 | Karnani Vikram | President and CEO | Tax withholding | 11,296 | $46.75 |
| 2026-02-10 | Smith Thomas B | EVP and Chief Medical Officer | Grant / award | 14,268 | $0.00 |
| 2026-02-10 | Smith Thomas B | EVP and Chief Medical Officer | Grant / award | 22,774 | $0.00 |
| 2026-02-10 | Smith Thomas B | EVP and Chief Medical Officer | Tax withholding | 5,897 | $46.75 |
| 2026-02-10 | Smith Thomas B | EVP and Chief Medical Officer | Tax withholding | 11,538 | $46.75 |
| 2026-02-10 | Tupper Colleen | EVP & Chief Financial Officer | Grant / award | 26,421 | $0.00 |
| 2026-02-10 | Tupper Colleen | EVP & Chief Financial Officer | Grant / award | 32,734 | $0.00 |
| 2026-02-10 | Tupper Colleen | EVP & Chief Financial Officer | Tax withholding | 11,861 | $46.75 |
| 2026-02-10 | Tupper Colleen | EVP & Chief Financial Officer | Tax withholding | 26,679 | $46.75 |
| 2026-02-10 | Dreyer Scott | EVP & Chief Commercial Officer | Grant / award | 19,023 | $0.00 |
| 2026-02-10 | Dreyer Scott | EVP & Chief Commercial Officer | Grant / award | 30,702 | $0.00 |
| 2026-02-10 | Dreyer Scott | EVP & Chief Commercial Officer | Tax withholding | 9,977 | $46.75 |
| 2026-02-10 | Dreyer Scott | EVP & Chief Commercial Officer | Tax withholding | 21,615 | $46.75 |
| 2025-12-08 | Dreyer Scott | EVP & Chief Commercial Officer | Option exercise | 17,600 | $15.90 |
| 2025-12-08 | Dreyer Scott | EVP & Chief Commercial Officer | Open market sale | 11,125 | $47.89 |
| 2025-12-08 | Dreyer Scott | EVP & Chief Commercial Officer | Open market sale | 6,475 | $48.66 |
| 2025-12-05 | Balice-Gordon Rita J. | Reporting person | Open market sale | 3,650 | $47.03 |
| 2025-11-12 | Karnani Vikram | President and CEO | Tax withholding | 8,983 | $47.35 |
| 2025-11-12 | Fallon John A. | Reporting person | Option exercise | 15,000 | $16.49 |
| 2025-11-12 | Fallon John A. | Reporting person | Option exercise | 19,853 | $9.33 |
| 2025-11-12 | Fallon John A. | Reporting person | Open market sale | 34,853 | $47.21 |
| 2025-11-06 | Tupper Colleen | EVP & Chief Financial Officer | Open market sale | 25,142 | $40.38 |
| 2025-11-06 | Tupper Colleen | EVP & Chief Financial Officer | Open market sale | 4,858 | $41.28 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 02:57 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-19 | 8-K | 2026-10-15 | View on SEC.gov → |
| 2026-08-13 | 8-K | 2026-08-12 | View on SEC.gov → |
| 2026-08-06 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-06 | 8-K | 2026-08-06 | View on SEC.gov → |
| 2026-06-10 | 4 | 2026-06-08 | View on SEC.gov → |
| 2026-05-20 | 4 | 2026-05-18 | View on SEC.gov → |
| 2026-05-18 | 4 | 2026-05-14 | View on SEC.gov → |
| 2026-05-18 | 4 | 2026-05-14 | View on SEC.gov → |
| 2026-05-18 | 4 | 2026-05-14 | View on SEC.gov → |
| 2026-05-18 | 4 | 2026-05-14 | View on SEC.gov → |
| 2026-05-18 | 4 | 2026-05-14 | View on SEC.gov → |
| 2026-05-18 | 4 | 2026-05-14 | View on SEC.gov → |
Recent news
Headlines about COLL (Collegium Pharmaceutical, Inc.). Links open the publisher — we don’t host full articles.
-
(COLL) Price Dynamics and Execution-Aware Positioning
Stock Traders Daily · 2026-10-21 -
Collegium Pharmaceutical Announces Seven ADHD Abstracts Accepted for AACAP and NEI Fall Congresses
Quiver Quantitative · 2026-10-21 -
Collegium to Present Pediatric and Real-World Research Across ADHD Portfolio at AACAP and NEI Fall Congresses
Yahoo · 2026-10-21 -
Zacks upgrades Collegium Pharmaceutical stock to strong buy
AD HOC NEWS · 2026-10-20 -
Collegium resolves Nucynta patent dispute with Grünenthal
Seeking Alpha · 2026-10-19 -
Collegium Pharmaceutical And Grünenthal Enter Settlement Agreement On Oct 15, 2026; Terminates Grünenthal License And Consent Agreement For Territory Effective Oct 15, 2026; Co. To Pay Grünenthal $17M In Settlement
Benzinga · 2026-10-19 -
COLL vs. DSNKY: Which Stock Is the Better Value Option?
Yahoo · 2026-10-19 -
COLL Nov 2026 30.000 call (COLL261120C00030000) Interactive Stock Chart
Yahoo! Finance Canada · 2026-10-19
No headlines in this category right now — try “All”.